A citation-based method for searching scientific literature

B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh, D B Rawlins, N C Goodwin, R Mabon, B A Harrison, A Wilson, A Sands, D R Powell. Clin Pharmacol Ther 2012
Times Cited: 156







List of co-cited articles
940 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Biology of human sodium glucose transporters.
Ernest M Wright, Donald D F Loo, Bruce A Hirayama. Physiol Rev 2011
682
36

LX4211 increases serum glucagon-like peptide 1 and peptide YY levels by reducing sodium/glucose cotransporter 1 (SGLT1)-mediated absorption of intestinal glucose.
David R Powell, Melinda Smith, Jennifer Greer, Angela Harris, Sharon Zhao, Christopher DaCosta, Faika Mseeh, Melanie K Shadoan, Arthur Sands, Brian Zambrowicz,[...]. J Pharmacol Exp Ther 2013
114
35

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
33

Na(+)-D-glucose cotransporter SGLT1 is pivotal for intestinal glucose absorption and glucose-dependent incretin secretion.
Valentin Gorboulev, Annette Schürmann, Volker Vallon, Helmut Kipp, Alexander Jaschke, Dirk Klessen, Alexandra Friedrich, Stephan Scherneck, Timo Rieg, Robyn Cunard,[...]. Diabetes 2012
393
29

Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor.
Pablo Lapuerta, Brian Zambrowicz, Paul Strumph, Arthur Sands. Diab Vasc Dis Res 2015
65
41

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
187
27

Selective sodium-dependent glucose transporter 1 inhibitors block glucose absorption and impair glucose-dependent insulinotropic peptide release.
Robert L Dobbins, Frank L Greenway, Lihong Chen, Yaping Liu, Sharon L Breed, Susan M Andrews, Jeffrey A Wald, Ann Walker, Chari D Smith. Am J Physiol Gastrointest Liver Physiol 2015
63
41

Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Arthur T Sands, Brian P Zambrowicz, Julio Rosenstock, Pablo Lapuerta, Bruce W Bode, Satish K Garg, John B Buse, Phillip Banks, Rubina Heptulla, Marc Rendell,[...]. Diabetes Care 2015
121
25

Improved glycemic control in mice lacking Sglt1 and Sglt2.
David R Powell, Christopher M DaCosta, Jason Gay, Zhi-Ming Ding, Melinda Smith, Jennifer Greer, Deon Doree, Sabrina Jeter-Jones, Faika Mseeh, Lawrence A Rodriguez,[...]. Am J Physiol Endocrinol Metab 2013
90
22

Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.
Ele Ferrannini, Elza Muscelli, Silvia Frascerra, Simona Baldi, Andrea Mari, Tim Heise, Uli C Broedl, Hans-Juergen Woerle. J Clin Invest 2014
599
20

Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
409
20

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors.
R Grempler, L Thomas, M Eckhardt, F Himmelsbach, A Sauer, D E Sharp, R A Bakker, M Mark, T Klein, P Eickelmann. Diabetes Obes Metab 2012
341
20

Greater dose-ranging effects on A1C levels than on glucosuria with LX4211, a dual inhibitor of SGLT1 and SGLT2, in patients with type 2 diabetes on metformin monotherapy.
Julio Rosenstock, William T Cefalu, Pablo Lapuerta, Brian Zambrowicz, Ike Ogbaa, Phillip Banks, Arthur Sands. Diabetes Care 2015
46
43

Effects of LX4211, a dual SGLT1/SGLT2 inhibitor, plus sitagliptin on postprandial active GLP-1 and glycemic control in type 2 diabetes.
Brian Zambrowicz, Zhi-Ming Ding, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Melinda Smith, Dennis Ruff, Arthur Sands,[...]. Clin Ther 2013
65
27

Phlorizin: a review.
Joel R L Ehrenkranz, Norman G Lewis, C Ronald Kahn, Jesse Roth. Diabetes Metab Res Rev 2005
491
18

Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia.
Timo Rieg, Takahiro Masuda, Maria Gerasimova, Eric Mayoux, Kenneth Platt, David R Powell, Scott C Thomson, Hermann Koepsell, Volker Vallon. Am J Physiol Renal Physiol 2014
145
18

Effect of LX4211 on glucose homeostasis and body composition in preclinical models.
David R Powell, Christopher M DaCosta, Melinda Smith, Deon Doree, Angela Harris, Lindsey Buhring, William Heydorn, Amr Nouraldeen, Wendy Xiong, Padmaja Yalamanchili,[...]. J Pharmacol Exp Ther 2014
36
47

Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes.
Wei Meng, Bruce A Ellsworth, Alexandra A Nirschl, Peggy J McCann, Manorama Patel, Ravindar N Girotra, Gang Wu, Philip M Sher, Eamonn P Morrison, Scott A Biller,[...]. J Med Chem 2008
362
17

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
17

KGA-2727, a novel selective inhibitor of a high-affinity sodium glucose cotransporter (SGLT1), exhibits antidiabetic efficacy in rodent models.
Toshihide Shibazaki, Masaki Tomae, Yukiko Ishikawa-Takemura, Nobuhiko Fushimi, Fumiaki Itoh, Mitsuhiko Yamada, Masayuki Isaji. J Pharmacol Exp Ther 2012
48
33

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members.
Jian Chen, Sandy Williams, Samantha Ho, Howard Loraine, Deborah Hagan, Jean M Whaley, John N Feder. Diabetes Ther 2010
148
16

Canagliflozin lowers postprandial glucose and insulin by delaying intestinal glucose absorption in addition to increasing urinary glucose excretion: results of a randomized, placebo-controlled study.
David Polidori, Sue Sha, Sunder Mudaliar, Theodore P Ciaraldi, Atalanta Ghosh, Nicole Vaccaro, Kristin Farrell, Paul Rothenberg, Robert R Henry. Diabetes Care 2013
179
16

Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes.
Hassan Rahmoune, Paul W Thompson, Joanna M Ward, Chari D Smith, Guizhu Hong, John Brown. Diabetes 2005
494
15

Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
Caroline Bonner, Julie Kerr-Conte, Valéry Gmyr, Gurvan Queniat, Ericka Moerman, Julien Thévenet, Cédric Beaucamps, Nathalie Delalleau, Iuliana Popescu, Willy J Malaisse,[...]. Nat Med 2015
372
15

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
146
15

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
77
19

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?
Jiwen Jim Liu, TaeWeon Lee, Ralph A DeFronzo. Diabetes 2012
132
14

Localizations of Na(+)-D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart.
Ivana Vrhovac, Daniela Balen Eror, Dirk Klessen, Christa Burger, Davorka Breljak, Ognjen Kraus, Nikola Radović, Stipe Jadrijević, Ivan Aleksic, Thorsten Walles,[...]. Pflugers Arch 2015
134
14

Glucose/galactose malabsorption caused by a defect in the Na+/glucose cotransporter.
E Turk, B Zabel, S Mundlos, J Dyer, E M Wright. Nature 1991
277
14

Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus.
Panai Song, Akira Onishi, Hermann Koepsell, Volker Vallon. Expert Opin Ther Targets 2016
69
20


Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
94
14

Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects.
Brian Zambrowicz, Ike Ogbaa, Kenny Frazier, Phillip Banks, Anne Turnage, Joel Freiman, Kristi A Boehm, Dennis Ruff, David Powell, Arthur Sands. Clin Ther 2013
44
29


Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production.
Aurora Merovci, Carolina Solis-Herrera, Giuseppe Daniele, Roy Eldor, Teresa Vanessa Fiorentino, Devjit Tripathy, Juan Xiong, Zandra Perez, Luke Norton, Muhammad A Abdul-Ghani,[...]. J Clin Invest 2014
459
13

Sodium-Glucose Cotransporter Inhibitors: Effects on Renal and Intestinal Glucose Transport: From Bench to Bedside.
Sunder Mudaliar, David Polidori, Brian Zambrowicz, Robert R Henry. Diabetes Care 2015
121
13

Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
13

LX4211 therapy reduces postprandial glucose levels in patients with type 2 diabetes mellitus and renal impairment despite low urinary glucose excretion.
Brian Zambrowicz, Pablo Lapuerta, Paul Strumph, Phillip Banks, Alan Wilson, Ike Ogbaa, Arthur Sands, David Powell. Clin Ther 2015
24
54


SGLT2 mediates glucose reabsorption in the early proximal tubule.
Volker Vallon, Kenneth A Platt, Robyn Cunard, Jana Schroth, Jean Whaley, Scott C Thomson, Hermann Koepsell, Timo Rieg. J Am Soc Nephrol 2011
288
12

Revised immunolocalization of the Na+-D-glucose cotransporter SGLT1 in rat organs with an improved antibody.
Daniela Balen, Marija Ljubojevic, Davorka Breljak, Hrvoje Brzica, Vilim Zlender, Hermann Koepsell, Ivan Sabolic. Am J Physiol Cell Physiol 2008
104
12

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
688
12

SGLT2 Inhibitors May Predispose to Ketoacidosis.
Simeon I Taylor, Jenny E Blau, Kristina I Rother. J Clin Endocrinol Metab 2015
255
12

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.
Ele Ferrannini, Anna Solini. Nat Rev Endocrinol 2012
249
11

Human cardiomyocytes express high level of Na+/glucose cotransporter 1 (SGLT1).
Lubing Zhou, Ellen V Cryan, Michael R D'Andrea, Stanley Belkowski, Bruce R Conway, Keith T Demarest. J Cell Biochem 2003
127
11

SGLT2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice.
Volker Vallon, Maria Gerasimova, Michael A Rose, Takahiro Masuda, Joseph Satriano, Eric Mayoux, Hermann Koepsell, Scott C Thomson, Timo Rieg. Am J Physiol Renal Physiol 2014
247
11


Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.
Charles S Hummel, Chuan Lu, Donald D F Loo, Bruce A Hirayama, Andrew A Voss, Ernest M Wright. Am J Physiol Cell Physiol 2011
148
11

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.
Sumihiro Nomura, Shigeki Sakamaki, Mitsuya Hongu, Eiji Kawanishi, Yuichi Koga, Toshiaki Sakamoto, Yasuo Yamamoto, Kiichiro Ueta, Hirotaka Kimata, Keiko Nakayama,[...]. J Med Chem 2010
197
11

Probing SGLT2 as a therapeutic target for diabetes: basic physiology and consequences.
Linda A Gallo, Ernest M Wright, Volker Vallon. Diab Vasc Dis Res 2015
169
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.